Search
for
Sort by
Research 30 of 1000+
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- The Influence of Flightless I: Regeneration versus Wound Healing
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Diseases of the Canine Prostate Gland
- RASopathic Skin Eruptions during Vemurafenib Therapy
- Management of Toxicities of Targeted Therapies
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Biological therapy in the treatment of melanoma
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- The PDGF/PDGFR pathway as a drug target
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Regulation of melanocyte stem cell behavior by the niche microenvironment
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
- B-Raf and C-Raf Are Required for Melanocyte Stem Cell Self-Maintenance
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors
- Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies